Merck’s RotaTeq Post-Marketing Study Will Center On Safety
This article was originally published in The Pink Sheet Daily
Executive Summary
The study will enroll 44,000 infants immunized with the rotavirus vaccine, which was approved Feb. 3.
You may also be interested in...
GSK’s Rotarix Gets FDA Vaccines Advisory Committee Review
Feb. 20 meeting to focus on product safety for Rotarix, which would have a shorter dosing schedule than Merck’s RotaTeq and target more virus types.
GSK’s Rotarix Gets FDA Vaccines Advisory Committee Review
Feb. 20 meeting to focus on product safety for Rotarix, which would have a shorter dosing schedule than Merck’s RotaTeq and target more virus types.
GSK Rotarix Data Show Efficacy Against Virus Types Representing 98 Percent Of Rotavirus Disease
Data formed the basis of GSK’s BLA application for the rotavirus vaccine in the U.S., the company tells “The Pink Sheet” DAILY.